PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Life sciences companies have decided to chop hundreds of Bay Area jobs in a fresh wave of layoffs that hint at ongoing ...

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.